A Phase 3 interventional study of Leuprolide Acetate 45 mg in Precocious Puberty, Central, sponsored by Tolmar Inc.. Completed at 20 sites in 6 countries. Open to participants aged 2 Years to 9 Years. Per ClinicalTrials.gov, last updated 2020-06-02.
Sponsored by Tolmar Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing leuprolide in Puberty, Precocious — 2 open to participants now, 2 under way, 1 of them phase 3. Leuprolide · Puberty, Precocious.
Among the 14 studies testing leuprolide in Puberty, Precocious, this one is the 8th largest by enrollment, is one of 2 that started in 2015, is one of 6 in phase 3, and was the 7th registered.
75 studies on the registry are indexed under Puberty, Precocious; 18 are open to participants now.
Browse Puberty, Precocious studies →2 of the 14 studies testing leuprolide in Puberty, Precocious are open now, in 1 country. Recruiting first, the newest first:
LG Chem · Sites in Korea, Republic of
Ages up to 10
Daewoong Pharmaceutical Co. LTD. · Sites in Korea, Republic of
Ages 4–10
By country, each count listing its studies:
Leuprolide: first FDA approval 1985 (LUPRON), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 14 Puberty, Precocious studies recruiting now, 2 (14%) set no upper age limit and 9 (64%) stop at 75 or younger; 14 take children under 18; 2 take healthy volunteers.
This study: 2 Years to 9 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 1991; this study’s year is marked. 2 started in 2015.
This study's enrollment of 64 is close to the median of 64 across 47 interventional studies indexed under Puberty, Precocious.
Median enrollment 68 across the 14 interventional studies. Of the 9 that completed or were terminated, 6 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 14 have an industry lead sponsor. The 10 most frequent:
Tolmar Inc. is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
Tolmar Inc. has 1 study filed under Puberty, Precocious — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 14 studies testing leuprolide in Puberty, Precocious, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study determines the effectiveness of leuprolide acetate 45 mg for injectable suspension for treatment of children with Central Precocious Puberty.
Leuprolide acetate is a GnRH agonist that inhibits pituitary gonadotropin secretion by binding to the GnRH receptors and blocking downstream hormone synthesis. The steady decrease in hormone synthesis (LH and FSH) leads to a suppression of testicular and ovarian steroidogenesis. In children with CPP, this steady decrease in hormone synthesis disrupts the progression of puberty.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Leuprolide acetate 45 mg will be administered as a subcutaneous injection at 6-month intervals for the 12 month study period.
Drug: Leuprolide Acetate 45 mg
Subcutaneous injection
Percentage of Participants With Suppression of Peak-Stimulated Luteinizing Hormone at 6 Months.
Luteinizing Hormone (LH) suppression is defined as peak-stimulated LH \<4 IU/L. Peak stimulated LH refers to the maximum LH concentration measured 30 minutes after a gonadotropin-releasing hormone agonst (GnRHa) stimulation test.
Time frame: 6 months
Percentage of Subjects With Suppression of Luteinizing Hormone Measured by Blood Levels.
Percentage of subjects with suppressed serum LH concentrations(\<4 IU/L) 30 minutes post GnRHa stimulation test at all assessed timepoints.
Time frame: Week 12, Week 24, Week 36, and Week 48
Changes in Height Velocity (Growth Rate)
Changes in height velocity (growth rate) at all study timepoints after Screening to end of study. Growth velocity is defined for each visit as change from baseline / \[(number of weeks since baseline)/52\]. Week 48: Change from Week 24 growth velocity is defined as change from week 24 to week 48 / \[(number of weeks since week 24)/52\].
Time frame: Week 4, Week 12, Week 20, Week 24, Week 36, Week 44, and Week 48
Bone Age Ratio to Chronological Age at Time of Measurement
Bone Age Ratio to Chronological Age at Time of Measurement is bone age/age at bone age assessment.
Time frame: Week 24 and Week 48
Percent Change From Baseline in Height
The percent change from baseline in height at each available post-baseline measurement. Percent change is defined as (((change from Baseline)/(Baseline)) x 100).
Time frame: Week 4, Week 12, Week 20, Week 24, Week 36, Week 44, and Week 48
Tanner Scores: Boys - Development of External Genitalia
Sexual development (physical signs) in puberty were assessed by Tanner staging, a system developed by Marshall and Tanner to categorize pubertal maturation. Tanner stages are commonly used to categorize pubertal maturation in terms of sequence, timing and tempo. Tanner Stages: the minimum is Stage 1 = pre-pubertal physical characteristics and the maximum is Stage 5 = fully matured (adult) physical characteristics.
Time frame: Baseline, Week 12, Week 24, Week 36, and Week 48
Tanner Scores: Boys - Development of External Genitalia (Change From Baseline)
Sexual development (physical signs) in puberty were assessed by Tanner staging, a system developed by Marshall and Tanner to categorize pubertal maturation. Tanner stages are commonly used to categorize pubertal maturation in terms of sequence, timing and tempo. Tanner Stages: the minimum is Stage 1 = pre-pubertal physical characteristics and the maximum is Stage 5 = fully matured (adult) physical characteristics.
Time frame: Week 12, Week 24, Week 36, and Week 48
Tanner Scores: Boys and Girls - Pubic Hair
Sexual development (physical signs) in puberty were assessed by Tanner staging, a system developed by Marshall and Tanner to categorize pubertal maturation. Tanner stages are commonly used to categorize pubertal maturation in terms of sequence, timing and tempo. Tanner Stages: the minimum is Stage 1 = pre-pubertal physical characteristics and the maximum is Stage 5 = fully matured (adult) physical characteristics.
Time frame: Baseline, Week 12, Week 24, Week 36, and Week 48
Tanner Scores: Boys and Girls - Pubic Hair (Change From Baseline)
Sexual development (physical signs) in puberty were assessed by Tanner staging, a system developed by Marshall and Tanner to categorize pubertal maturation. Tanner stages are commonly used to categorize pubertal maturation in terms of sequence, timing and tempo. Tanner Stages: the minimum is Stage 1 = pre-pubertal physical characteristics and the maximum is Stage 5 = fully matured (adult) physical characteristics.
Time frame: Week 12, Week 24, Week 36, and Week 48
Tanner Scores: Girls - Breast Development
Sexual development (physical signs) in puberty were assessed by Tanner staging, a system developed by Marshall and Tanner to categorize pubertal maturation. Tanner stages are commonly used to categorize pubertal maturation in terms of sequence, timing and tempo. Tanner Stages: the minimum is Stage 1 = pre-pubertal physical characteristics and the maximum is Stage 5 = fully matured (adult) physical characteristics.
Time frame: Baseline, Week 12, Week 24, Week 36, and Week 48
Tanner Scores: Girls - Breast Development (Change From Baseline)
Sexual development (physical signs) in puberty were assessed by Tanner staging, a system developed by Marshall and Tanner to categorize pubertal maturation. Tanner stages are commonly used to categorize pubertal maturation in terms of sequence, timing and tempo. Tanner Stages: the minimum is Stage 1 = pre-pubertal physical characteristics and the maximum is Stage 5 = fully matured (adult) physical characteristics.
Time frame: Week 12, Week 24, Week 36, and Week 48
Height
Height at each available measurement point. Baseline is defined as the last non-missing height measurement collected prior to or on the date of first injection.
Time frame: Screening, Baseline, Week 4, Week 12, Week 20, Week 24, Week 36, Week 44, and Week 48
Bone Age
Bone Age at each available measurement point.
Time frame: Baseline, Week 24, and Week 48
Bone Age Progression
Bone age progression at each available post-baseline measurement point. Bone age progression is defined as (((change from baseline)/(baseline)) x 100), which is percent change from baseline.
Time frame: Week 24 and Week 48
Bone Age Ratio to Chronological Age at Time of Measurement (Percent Change From Baseline)
Bone Age Ratio to Chronological Age at Time of Measurement is bone age/age at bone age assessment.
Time frame: Week 24 and Week 48
Bone Age Ratio to Chronological Age at Start of Study (Percent Change From Baseline)
Bone age advancement was evaluated relative to chronological age at each given measurement point. Percent change from baseline is: 100 x (the change from baseline value at the post-baseline visit / baseline value).
Time frame: Week 24 and Week 48
Bone Age Ratio to Chronological Age at Start of Study
Bone age advancement was evaluated relative to chronological age at each given measurement point. Bone Age Ratio to Chronological Age at Start of Study is bone age/age at first injection.
Time frame: Baseline, Week 24, and Week 48
GnRH Antagonist Evaluation
GnRH Antagonist Evaluation occurred for the two week period following each treatment and at each visit to assess flare symptoms. The percent of subjects who affirm (or whose parent/guardian affirms) each symptom domain in the global interview.
Time frame: Week 2, Week 4, Week 12, Week 20, Week 24, Week 26, Week 36, Week 44, and Week 48
Percentage of Subjects With Suppression of FSH, Estradiol, Oestradiol (HS), and Testosterone Measured by Blood Levels.
The percentage of subjects with FSH, estradiol and testosterone suppression to prepubertal levels (FSH \< 2.5 mIU/mL, estradiol \< 20 pg/mL and testosterone \< 28.4 ng/dL) at each available time point.
Time frame: Week 12, Week 24, Week 36, and Week 48
Changes in the Ratio of LH/FSH
Changes in ratio of LH/FSH at each time point from Screening to End of Study
Time frame: Screening (Pre&Post GnRHa Stim Test), Baseline (0,1,4,6 hours Post-Injection), Week 4, Week 12 (Pre&Post GnRHa Stim Test), Week 20, Week 24 (Pre&Post GnRHa Stim Test), Week 36 (Pre&Post GnRHa Stim Test), Week 44, and Week 48 (Pre&Post GnRHa Stim Test)
| Milestone | Assigned Intervention |
|---|---|
| Started | 64 |
| Completed | 60 |
| Not completed | 4 |
Luteinizing Hormone (LH) suppression is defined as peak-stimulated LH \<4 IU/L. Peak stimulated LH refers to the maximum LH concentration measured 30 minutes after a gonadotropin-releasing hormone agonst (GnRHa) stimulation test.
| Participants | Assigned Intervention |
|---|---|
| Percentage of Participants With Suppression of Peak-Stimulated Luteinizing Hormone at 6 Months. | 54 |
Percentage of subjects with suppressed serum LH concentrations(\<4 IU/L) 30 minutes post GnRHa stimulation test at all assessed timepoints.
| Participants | Assigned Intervention |
|---|---|
| Visit 3, Week 12 | 51 |
| Visit 5, Week 24 | 54 |
| Visit 6, Week 36 | 50 |
| End of Treatment, Week 48 | 50 |
Changes in height velocity (growth rate) at all study timepoints after Screening to end of study. Growth velocity is defined for each visit as change from baseline / \[(number of weeks since baseline)/52\]. Week 48: Change from Week 24 growth velocity is defined as change from week 24 to week 48 / \[(number of weeks since week 24)/52\].
| cm/year | Assigned Intervention |
|---|---|
| Visit 2, Week 4 | 8.89 ± 13.128 |
| Visit 3, Week 12 | 8.30 ± 4.782 |
| Visit 4, Week 20 | 6.66 ± 3.155 |
| Visit 5, Week 24 | 6.90 ± 3.074 |
| Visit 6, Week 36 | 6.48 ± 2.272 |
| Visit 7, Week 44 | 6.23 ± 1.953 |
| End of Treatment, Week 48 | 6.37 ± 1.893 |
| End of Treatment, Week 48: Change from Week 24 | 5.79 ± 2.213 |
Bone Age Ratio to Chronological Age at Time of Measurement is bone age/age at bone age assessment.
| Ratio | Assigned Intervention |
|---|---|
| Baseline | 1.39 ± 0.160 |
| Visit 5, Week 24 | 1.34 ± 0.138 |
| End of Treatment, Week 48 | 1.32 ± 0.143 |
| Minimum Post-baseline Value | 1.30 ± 0.138 |
| Maximum Post-baseline Value | 1.36 ± 0.138 |
The percent change from baseline in height at each available post-baseline measurement. Percent change is defined as (((change from Baseline)/(Baseline)) x 100).
| Percent change | Assigned Intervention |
|---|---|
| Visit 2, Week 4 | 0.5 ± 0.78 |
| Visit 3, Week 12 | 1.4 ± 0.82 |
| Visit 4, Week 20 | 1.9 ± 0.89 |
| Visit 5, Week 24 | 2.3 ± 1.06 |
| Visit 6, Week 36 | 3.3 ± 1.17 |
| Visit 7, Week 44 | 3.9 ± 1.26 |
| End of Treatment, Week 48 | 4.3 ± 1.34 |
Sexual development (physical signs) in puberty were assessed by Tanner staging, a system developed by Marshall and Tanner to categorize pubertal maturation. Tanner stages are commonly used to categorize pubertal maturation in terms of sequence, timing and tempo. Tanner Stages: the minimum is Stage 1 = pre-pubertal physical characteristics and the maximum is Stage 5 = fully matured (adult) physical characteristics.
| Score on a scale | Assigned Intervention |
|---|---|
| Baseline | 3.0 ± 0.00 |
| Visit 3, Week 12 | 2.5 ± 0.71 |
| Visit 5, Week 24 | 2.5 ± 0.71 |
| Visit 6, Week 36 | 2.5 ± 0.71 |
| End of Treatment, Week 48 | 2.0 ± 0.00 |
Sexual development (physical signs) in puberty were assessed by Tanner staging, a system developed by Marshall and Tanner to categorize pubertal maturation. Tanner stages are commonly used to categorize pubertal maturation in terms of sequence, timing and tempo. Tanner Stages: the minimum is Stage 1 = pre-pubertal physical characteristics and the maximum is Stage 5 = fully matured (adult) physical characteristics.
| Score on a scale | Assigned Intervention |
|---|---|
| Visit 3, Week 12 | -0.5 ± 0.71 |
| Visit 5, Week 24 | -0.5 ± 0.71 |
| Visit 6, Week 36 | -0.5 ± 0.71 |
| End of Treatment, Week 48 | -1.0 ± 0.00 |
Sexual development (physical signs) in puberty were assessed by Tanner staging, a system developed by Marshall and Tanner to categorize pubertal maturation. Tanner stages are commonly used to categorize pubertal maturation in terms of sequence, timing and tempo. Tanner Stages: the minimum is Stage 1 = pre-pubertal physical characteristics and the maximum is Stage 5 = fully matured (adult) physical characteristics.
| Score on a scale | Assigned Intervention |
|---|---|
| Baseline | 2.3 ± 0.81 |
| Visit 3, Week 12 | 2.4 ± 0.89 |
| Visit 5, Week 24 | 2.5 ± 0.92 |
| Visit 6, Week 36 | 2.3 ± 0.94 |
| End of Treatment, Week 48 | 2.4 ± 0.95 |
Sexual development (physical signs) in puberty were assessed by Tanner staging, a system developed by Marshall and Tanner to categorize pubertal maturation. Tanner stages are commonly used to categorize pubertal maturation in terms of sequence, timing and tempo. Tanner Stages: the minimum is Stage 1 = pre-pubertal physical characteristics and the maximum is Stage 5 = fully matured (adult) physical characteristics.
| Score on a scale | Assigned Intervention |
|---|---|
| Visit 3, Week 12 | 0.1 ± 0.56 |
| Visit 5, Week 24 | 0.1 ± 0.59 |
| Visit 6, Week 36 | 0.1 ± 0.60 |
| End of Treatment, Week 48 | 0.1 ± 0.58 |
Sexual development (physical signs) in puberty were assessed by Tanner staging, a system developed by Marshall and Tanner to categorize pubertal maturation. Tanner stages are commonly used to categorize pubertal maturation in terms of sequence, timing and tempo. Tanner Stages: the minimum is Stage 1 = pre-pubertal physical characteristics and the maximum is Stage 5 = fully matured (adult) physical characteristics.
| Score on a scale | Assigned Intervention |
|---|---|
| Baseline | 3.2 ± 0.61 |
| Visit 3, Week 12 | 2.7 ± 0.90 |
| Visit 5, Week 24 | 2.6 ± 1.0 |
| Visit 6, Week 36 | 2.5 ± 0.89 |
| End of Treatment, Week 48 | 2.4 ± 0.93 |
Sexual development (physical signs) in puberty were assessed by Tanner staging, a system developed by Marshall and Tanner to categorize pubertal maturation. Tanner stages are commonly used to categorize pubertal maturation in terms of sequence, timing and tempo. Tanner Stages: the minimum is Stage 1 = pre-pubertal physical characteristics and the maximum is Stage 5 = fully matured (adult) physical characteristics.
| Score on a scale | Assigned Intervention |
|---|---|
| Visit 3, Week 12 | -0.5 ± 0.90 |
| Visit 5, Week 24 | -0.6 ± 0.87 |
| Visit 6, Week 36 | -0.6 ± 0.86 |
| End of Treatment, Week 48 | -0.7 ± 0.89 |
Height at each available measurement point. Baseline is defined as the last non-missing height measurement collected prior to or on the date of first injection.
| cm | Assigned Intervention |
|---|---|
| Screening | 136.17 ± 8.292 |
| Baseline | 136.61 ± 8.071 |
| Visit 2, Week 4 | 137.32 ± 8.201 |
| Visit 3, Week 12 | 138.52 ± 8.284 |
| Visit 4, Week 20 | 138.87 ± 8.070 |
| Visit 5, Week 24 | 139.78 ± 8.206 |
| Visit 6, Week 36 | 140.99 ± 8.374 |
| Visit 7, Week 44 | 141.81 ± 8.268 |
| End of Treatment, Week 48 | 142.37 ± 8.207 |
Bone Age at each available measurement point.
| years | Assigned Intervention |
|---|---|
| Baseline | 11.01 ± 1.307 |
| Visit 5, Week 24 | 11.30 ± 1.238 |
| End of Treatment, Week 48 | 11.65 ± 1.124 |
Bone age progression at each available post-baseline measurement point. Bone age progression is defined as (((change from baseline)/(baseline)) x 100), which is percent change from baseline.
| percent change | Assigned Intervention |
|---|---|
| Visit 5, Week 24 | 2.91 ± 4.607 |
| End of Treatment, Week 48 | 6.81 ± 5.741 |
| Minimum Post-Baseline Value | 2.91 ± 4.607 |
| Maximum Post-Baseline Value | 6.63 ± 5.736 |
Bone Age Ratio to Chronological Age at Time of Measurement is bone age/age at bone age assessment.
| percent change | Assigned Intervention |
|---|---|
| Visit 5, Week 24 | -3.25 ± 4.382 |
| End of Treatment, Week 48 | -4.90 ± 4.689 |
| Minimum Post-baseline Value | -6.15 ± 3.934 |
| Maximum Post-baseline Value | -1.89 ± 4.155 |
Bone age advancement was evaluated relative to chronological age at each given measurement point. Percent change from baseline is: 100 x (the change from baseline value at the post-baseline visit / baseline value).
| percent change | Assigned Intervention |
|---|---|
| Visit 5, Week 24 | 2.91 ± 4.607 |
| End of Treatment, Week 48 | 6.81 ± 5.741 |
| Minimum Post-baseline Value | 2.91 ± 4.607 |
| Maximum Post-baseline Value | 6.63 ± 5.736 |
Bone age advancement was evaluated relative to chronological age at each given measurement point. Bone Age Ratio to Chronological Age at Start of Study is bone age/age at first injection.
| Ratio | Assigned Intervention |
|---|---|
| Baseline | 1.38 ± 0.158 |
| Visit 5, Week 24 | 1.42 ± 0.153 |
| End of Treatment, Week 48 | 1.47 ± 0.178 |
| Minimum Post-baseline Value | 1.42 ± 0.153 |
| Maximum Post-baseline Value | 1.47 ± 0.176 |
GnRH Antagonist Evaluation occurred for the two week period following each treatment and at each visit to assess flare symptoms. The percent of subjects who affirm (or whose parent/guardian affirms) each symptom domain in the global interview.
| Participants | Assigned Intervention |
|---|---|
| Telephone Contact #1, Week 2 — Any GnRH Antagonist Conditions Reported? | 15 |
| Telephone Contact #1, Week 2 — Flare or hot flashes | 4 |
| Telephone Contact #1, Week 2 — Injection site reactions | 11 |
| Telephone Contact #1, Week 2 — Burning/Stinging | 0 |
| Telephone Contact #1, Week 2 — Pain | 9 |
| Telephone Contact #1, Week 2 — Bruising | 3 |
| Telephone Contact #1, Week 2 — Redness | 0 |
| Telephone Contact #1, Week 2 — Difficulty in urination | 1 |
| Telephone Contact #1, Week 2 — Bone Pain | 1 |
| Telephone Contact #1, Week 2 — Aggravation of weakness or other muscle symptoms | 0 |
| Telephone Contact #1, Week 2 — Onset of Allergic reactions | 0 |
| Telephone Contact #1, Week 2 — No GnRH Antagonist conditions reported? | 15 |
| Visit 2, Week 4 — Any GnRH Antagonist Conditions Reported? | 4 |
| Visit 2, Week 4 — Flare or hot flashes | 2 |
| Visit 2, Week 4 — Injection site reactions | 1 |
| Visit 2, Week 4 — Burning/Stinging | 0 |
| Visit 2, Week 4 — Pain | 1 |
| Visit 2, Week 4 — Bruising | 0 |
| Visit 2, Week 4 — Redness | 0 |
| Visit 2, Week 4 — Difficulty in urination | 0 |
| Visit 2, Week 4 — Bone Pain | 1 |
| Visit 2, Week 4 — Aggravation of weakness or other muscle symptoms | 0 |
| Visit 2, Week 4 — Onset of Allergic reactions | 0 |
| Visit 2, Week 4 — No GnRH Antagonist conditions reported? | 53 |
| Visit 3, Week 12 — Any GnRH Antagonist Conditions Reported? | 5 |
| Visit 3, Week 12 — Flare or hot flashes | 1 |
| Visit 3, Week 12 — Injection site reactions | 3 |
| Visit 3, Week 12 — Burning/Stinging | 0 |
| Visit 3, Week 12 — Pain | 2 |
| Visit 3, Week 12 — Bruising | 0 |
| Visit 3, Week 12 — Redness | 1 |
| Visit 3, Week 12 — Difficulty in urination | 0 |
| Visit 3, Week 12 — Bone Pain | 1 |
| Visit 3, Week 12 — Aggravation of weakness or other muscle symptoms | 0 |
| Visit 3, Week 12 — Onset of Allergic reactions | 0 |
| Visit 3, Week 12 — No GnRH Antagonist conditions reported? | 48 |
| Visit 4, Week 20 — Any GnRH Antagonist Conditions Reported? | 3 |
| Visit 4, Week 20 — Flare or hot flashes | 1 |
| Visit 4, Week 20 — Injection site reactions | 1 |
| Visit 4, Week 20 — Burning/Stinging | 0 |
| Visit 4, Week 20 — Pain | 1 |
| Visit 4, Week 20 — Bruising | 0 |
| Visit 4, Week 20 — Redness | 0 |
| Visit 4, Week 20 — Difficulty in urination | 0 |
| Visit 4, Week 20 — Bone Pain | 1 |
| Visit 4, Week 20 — Aggravation of weakness or other muscle symptoms | 0 |
| Visit 4, Week 20 — Onset of Allergic reactions | 0 |
| Visit 4, Week 20 — No GnRH Antagonist conditions reported? | 53 |
| Visit 5, Week 24 — Any GnRH Antagonist Conditions Reported? | 3 |
| Visit 5, Week 24 — Flare or hot flashes | 1 |
| Visit 5, Week 24 — Injection site reactions | 1 |
| Visit 5, Week 24 — Burning/Stinging | 0 |
| Visit 5, Week 24 — Pain | 0 |
| Visit 5, Week 24 — Bruising | 0 |
| Visit 5, Week 24 — Redness | 0 |
| Visit 5, Week 24 — Difficulty in urination | 0 |
| Visit 5, Week 24 — Bone Pain | 1 |
| Visit 5, Week 24 — Aggravation of weakness or other muscle symptoms | 0 |
| Visit 5, Week 24 — Onset of Allergic reactions | 0 |
| Visit 5, Week 24 — No GnRH Antagonist conditions reported? | 55 |
| Telephone Contact #2, Week 26 — Any GnRH Antagonist Conditions Reported? | 16 |
| Telephone Contact #2, Week 26 — Flare or hot flashes | 2 |
| Telephone Contact #2, Week 26 — Injection site reactions | 15 |
| Telephone Contact #2, Week 26 — Burning/Stinging | 0 |
| Telephone Contact #2, Week 26 — Pain | 15 |
| Telephone Contact #2, Week 26 — Bruising | 0 |
| Telephone Contact #2, Week 26 — Redness | 3 |
| Telephone Contact #2, Week 26 — Difficulty in urination | 0 |
| Telephone Contact #2, Week 26 — Bone Pain | 0 |
| Telephone Contact #2, Week 26 — Aggravation of weakness or other muscle symptoms | 0 |
| Telephone Contact #2, Week 26 — Onset of Allergic reactions | 0 |
| Telephone Contact #2, Week 26 — No GnRH Antagonist conditions reported? | 6 |
| Visit 6, Week 36 — Any GnRH Antagonist Conditions Reported? | 3 |
| Visit 6, Week 36 — Flare or hot flashes | 1 |
| Visit 6, Week 36 — Injection site reactions | 1 |
| Visit 6, Week 36 — Burning/Stinging | 0 |
| Visit 6, Week 36 — Pain | 1 |
| Visit 6, Week 36 — Bruising | 0 |
| Visit 6, Week 36 — Redness | 1 |
| Visit 6, Week 36 — Difficulty in urination | 1 |
| Visit 6, Week 36 — Bone Pain | 0 |
| Visit 6, Week 36 — Aggravation of weakness or other muscle symptoms | 0 |
| Visit 6, Week 36 — Onset of Allergic reactions | 0 |
| Visit 6, Week 36 — No GnRH Antagonist conditions reported? | 51 |
| Visit 7, Week 44 — Any GnRH Antagonist Conditions Reported? | 3 |
| Visit 7, Week 44 — Flare or hot flashes | 2 |
| Visit 7, Week 44 — Injection site reactions | 0 |
| Visit 7, Week 44 — Burning/Stinging | 0 |
| Visit 7, Week 44 — Pain | 0 |
| Visit 7, Week 44 — Bruising | 0 |
| Visit 7, Week 44 — Redness | 0 |
| Visit 7, Week 44 — Difficulty in urination | 0 |
| Visit 7, Week 44 — Bone Pain | 0 |
| Visit 7, Week 44 — Aggravation of weakness or other muscle symptoms | 0 |
| Visit 7, Week 44 — Onset of Allergic reactions | 1 |
| Visit 7, Week 44 — No GnRH Antagonist conditions reported? | 53 |
| End of Treatment, Week 48 — Any GnRH Antagonist Conditions Reported? | 1 |
| End of Treatment, Week 48 — Flare or hot flashes | 1 |
| End of Treatment, Week 48 — Injection site reactions | 0 |
| End of Treatment, Week 48 — Burning/Stinging | 0 |
| End of Treatment, Week 48 — Pain | 0 |
| End of Treatment, Week 48 — Bruising | 0 |
| End of Treatment, Week 48 — Redness | 0 |
| End of Treatment, Week 48 — Difficulty in urination | 0 |
| End of Treatment, Week 48 — Bone Pain | 0 |
| End of Treatment, Week 48 — Aggravation of weakness or other muscle symptoms | 0 |
| End of Treatment, Week 48 — Onset of Allergic reactions | 0 |
| End of Treatment, Week 48 — No GnRH Antagonist conditions reported? | 57 |
The percentage of subjects with FSH, estradiol and testosterone suppression to prepubertal levels (FSH \< 2.5 mIU/mL, estradiol \< 20 pg/mL and testosterone \< 28.4 ng/dL) at each available time point.
| Participants | Assigned Intervention |
|---|---|
| Visit 3, Week 12 : FSH | 37 |
| Visit 3, Week 12 : Estradiol | 58 |
| Visit 3, Week 12 : Oestradiol (HS) | 56 |
| Visit 3, Week 12 : Testosterone | 2 |
| Visit 5, Week 24 : FSH | 41 |
| Visit 5, Week 24 : Estradiol | 59 |
| Visit 5, Week 24 : Oestradiol (HS) | 58 |
| Visit 5, Week 24 : Testosterone | 2 |
| Visit 6, Week 36 : FSH | 26 |
| Visit 6, Week 36 : Estradiol | 57 |
| Visit 6, Week 36 : Oestradiol (HS) | 56 |
| Visit 6, Week 36 : Testosterone | 2 |
| End of Treatment, Week 48 : FSH | 32 |
| End of Treatment, Week 48 : Estradiol | 56 |
| End of Treatment, Week 48 : Oestradiol (HS) | 55 |
| End of Treatment, Week 48 : Testosterone | 1 |
Changes in ratio of LH/FSH at each time point from Screening to End of Study
| Ratio | Assigned Intervention |
|---|---|
| Screening: Pre GnRHa Stimulation Test | 0.387 ± 0.4675 |
| Screening: Post GnRHa Stimulation Test | 2.187 ± 1.6713 |
| Baseline | 0.604 ± 0.9851 |
| Baseline: 1 hr Post Inj | 2.424 ± 2.1534 |
| Baseline: 1 hr Post Inj: Change from Baseline | 1.856 ± 1.7277 |
| Baseline: 4 hr Post Inj | 2.110 ± 2.3939 |
| Baseline: 4 hr Post Inj: Change from Baseline | 1.542 ± 2.0932 |
| Baseline: 6 hr Post Inj | 1.691 ± 1.7330 |
| Baseline: 6 hr Post Inj: Change from Baseline | 1.123 ± 1.4378 |
| Week 4 | 0.843 ± 1.0004 |
| Week 4: Change from Baseline | 0.233 ± 1.1425 |
| Week 12: Pre GnRHa Stim Test | 0.565 ± 0.9100 |
| Week 12: Pre GnRHa Stim Test: Change from Baseline | -0.050 ± 1.0423 |
| Week 12: Post GnRHa Stim Test | 1.342 ± 1.7934 |
| Week12: Post GnRHa Stim Test: Change from Baseline | 0.721 ± 1.7237 |
| Week 20 | 0.654 ± 0.9806 |
| Week 20: Change from Baseline | 0.068 ± 1.1859 |
| Week 24: Pre GnRHa Stim Test | 0.611 ± 0.9571 |
| Week 24: Pre GnRHa Stim Test: Change from Baseline | 0.007 ± 1.1818 |
| Week 24: Post GnRHa Stim Test | 1.320 ± 1.2843 |
| Week24: Post GnRHa Stim Test: Change from Baseline | 0.716 ± 1.4450 |
| Week 36: Pre GnRHa Stim Test | 0.474 ± 0.5249 |
| Week 36: Pre GnRHa Stim Test: Change from Baseline | -0.125 ± 1.0038 |
| Week 36: Post GnRHa Stim Test | 1.051 ± 1.4130 |
| Week36: Post GnRHa Stim Test: Change from Baseline | 0.461 ± 15374 |
| Week 44 | 0.517 ± 0.7846 |
| Week 44: Change from Baseline | -0.073 ± 1.0575 |
| Week 48: Pre GnRHa Stim Test | 0.557 ± 1.0957 |
| Week 48: Pre GnRHa Stim Test: Change from Baseline | -0.033 ± 1.2191 |
| Week 48: Post GnRHa Stim Test | 1.092 ± 1.5655 |
| Week48: Post GnRHa Stim Test: Change from Baselin | 0.509 ± 1.5780 |
Collected over Adverse events were collected from the time ICF was signed until End of Treatment (48 weeks). Any AEs related to study drug were followed for 28 days or through resolution, stabilization, until deemed clinically insignificant, or until the subject is lost to follow-up.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Assigned Intervention | 0/64 (0%) | 1/64 (1.6%) | 55/64 (85.9%) |
| Event | Assigned Intervention |
|---|---|
| WheezingRespiratory, thoracic and mediastinal disorders | 1/64 |
| RashSkin and subcutaneous tissue disorders | 1/64 |
| Event | Assigned Intervention |
|---|---|
| NasopharyngitisInfections and infestations | 14/64 |
| PyrexiaGeneral disorders | 11/64 |
| HeadacheNervous system disorders | 10/64 |
| CoughRespiratory, thoracic and mediastinal disorders | 8/64 |
| Abdominal painGastrointestinal disorders | 6/64 |
| NauseaGastrointestinal disorders | 5/64 |
| ConstipationGastrointestinal disorders | 4/64 |
| VomitingGastrointestinal disorders | 4/64 |
| Upper respiratory tract infectionInfections and infestations | 4/64 |
| BronchospasmRespiratory, thoracic and mediastinal disorders | 4/64 |
| Age, Continuous(years) | Assigned Intervention |
|---|---|
| Mean | 7.5 ± 0.89 |
| Sex: Female, Male(Participants) | Assigned Intervention |
|---|---|
| Female | 62 |
| Male | 2 |
| Race/Ethnicity, Customized(Participants) | Assigned Intervention |
|---|---|
| American Indian or Alaska Native | 5 |
| Asian | 3 |
| Black or African American | 15 |
| Native Hawaiian or Other Pacific Islander | 1 |
| White | 34 |
| Unwilling to Provide | 1 |
| Other | 5 |
| Hispanic or Latino | 36 |
| Not hispanic or Latino | 28 |
| Region of Enrollment(participants) | Assigned Intervention |
|---|---|
| New Zealand | 2 |
| Canada | 2 |
| Argentina | 13 |
| United States | 31 |
| Mexico | 7 |
| Chile | 9 |
| Luteinizing Hormone(IU/L) | Assigned Intervention |
|---|---|
| Mean | 23.46 ± 24.282 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Aug 2015 to primary completion in Sep 2018, 36 months.
Results were first posted in May 2020, 1 year 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Leuprolide
Tolmar Inc.